Science Explorer Back to mapMap
Discussion
Company · Modena · Italy

Tydock Pharma (Italy)

tydockpharma.comROR OpenAlex
Research works
16
▼ 5% vs 2018-21
Citations
283
17.3 per fractional work
Top-10% rate
9.0%
all institutions 10.0%
Open access
60%
world 40%
International
34%
world 18%
Tydock Pharma (Italy)

Not ranked overall: Tydock Pharma (Italy) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Tydock Pharma (Italy) work in?

In all years, 54% of research at Tydock Pharma (Italy) is in Health Sciences, 22% in Social Sciences. Its largest fields are Medicine (32%), Health Professions (22%), Economics, Econometrics and Finance (9%). It does 1.7× the world's share of Health Sciences.

Health Sciences: 9 fractional works · 54.2% of its workMedicine: 5 fractional works · 32.3% of its workCardiology and Cardiovascular Medicine: 1 fractional works · 7.1% of its workInfectious Diseases: 1 fractional works · 5.9% of its workPhysiology: 1 fractional works · 4.5% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 4.0% of its workSurgery: 0 fractional works · 3.1% of its workEpidemiology: 0 fractional works · 1.9% of its workNeurology: 0 fractional works · 1.3% of its workPharmacology: 0 fractional works · 1.3% of its workDermatology: 0 fractional works · 1.0% of its workEmergency Medicine: 0 fractional works · 1.0% of its workPathology and Forensic Medicine: 0 fractional works · 1.0% of its workOphthalmology: 0 fractional works · 0.4% of its workHealth Professions: 4 fractional works · 22.0% of its workGeneral Health Professions: 3 fractional works · 17.9% of its workSpeech and Hearing: 0 fractional works · 3.1% of its workOccupational Therapy: 0 fractional works · 1.0% of its workSocial Sciences: 4 fractional works · 22.1% of its workEconomics, Econometrics and Finance: 2 fractional works · 9.3% of its workEconomics and Econometrics: 2 fractional works · 9.3% of its workBusiness, Management and Accounting: 1 fractional works · 8.8% of its workStrategy and Management: 1 fractional works · 6.8% of its workManagement of Technology and Innovation: 0 fractional works · 2.0% of its workPsychology: 0 fractional works · 2.3% of its workExperimental and Cognitive Psychology: 0 fractional works · 2.0% of its workApplied Psychology: 0 fractional works · 0.3% of its workSocial Sciences: 0 fractional works · 1.7% of its workTransportation: 0 fractional works · 1.7% of its workPhysical Sciences: 2 fractional works · 13.2% of its workEngineering: 1 fractional works · 6.5% of its workElectrical and Electronic Engineering: 1 fractional works · 5.1% of its workBiomedical Engineering: 0 fractional works · 1.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workChemistry: 1 fractional works · 4.0% of its workOrganic Chemistry: 1 fractional works · 4.0% of its workPhysics and Astronomy: 0 fractional works · 1.3% of its workAtomic and Molecular Physics, and Optics: 0 fractional works · 1.3% of its workEnvironmental Science: 0 fractional works · 1.2% of its workManagement, Monitoring, Policy and Law: 0 fractional works · 0.7% of its workPollution: 0 fractional works · 0.5% of its workComputer Science: 0 fractional works · 0.2% of its workComputational Theory and Mathematics: 0 fractional works · 0.2% of its workLife Sciences: 2 fractional works · 10.4% of its workBiochemistry, Genetics and Molecular Biology: 1 fractional works · 7.3% of its workMolecular Biology: 1 fractional works · 4.2% of its workGenetics: 0 fractional works · 2.0% of its workMolecular Medicine: 0 fractional works · 1.0% of its workAgricultural and Biological Sciences: 0 fractional works · 1.0% of its workPlant Science: 0 fractional works · 1.0% of its workImmunology and Microbiology: 0 fractional works · 1.0% of its workMicrobiology: 0 fractional works · 1.0% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 1.0% of its workPharmacology: 0 fractional works · 1.0% of its workALL ITS WORKTydock Pharma(Italy)16fractional works, all years
Life Sciences10%Physical Sciences13%Health Sciences54%Social Sciences22%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 15 fields, with their numbers
    1. Medicine532.3%
    2. Health Professions422.0%
    1. Economics, Econometrics and Finance29.3%
    2. Business, Management and Accounting18.8%
    3. Psychology02.3%
    4. Social Sciences01.7%
    1. Engineering16.5%
    2. Chemistry14.0%
    3. Physics and Astronomy01.3%
    4. Environmental Science01.2%
    5. Computer Science00.2%
    1. Biochemistry, Genetics and Molecular Biology17.3%
    2. Agricultural and Biological Sciences01.0%
    3. Immunology and Microbiology01.0%
    4. Pharmacology, Toxicology and Pharmaceutics01.0%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 1.68× its world share, 0 worksBiochemistry, Geneti…Computer Science: 0.10× its world share, 0 worksComputer ScienceEnvironmental Science: 0.55× its world share, 0 worksEnvironmental ScienceHealth Professions: 0.44× its world share, 0 worksHealth ProfessionsMedicine: 1.92× its world share, 2 worksMedicineBusiness, Management and Accounting: 3.37× its world share, 0 worksBusiness, Management…Economics, Econometrics and Finance: 17.44× its world share, 2 worksEconomics, Econometr…Psychology: 0.38× its world share, 0 worksPsychology1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Economics, Econometrics and Finance, 17.4×. Every wedge is a field page.

All 8 fields, with their numbers
  1. Economics, Econometrics and Finance17.44×2 works
  2. Business, Management and Accounting3.37×0 works
  3. Medicine1.92×2 works
  4. Biochemistry, Genetics and Molecular Biology1.68×0 works
  5. Environmental Science0.55×0 works
  6. Health Professions0.44×0 works
  7. Psychology0.38×0 works
  8. Computer Science0.10×0 works

Who are the top researchers at Tydock Pharma (Italy)?

Ranked on the quality score, Wilma King lead among researchers whose main affiliation is Tydock Pharma (Italy).

  1. 1 Wilma King Italy · #2,334,912 worldwide 245 citations · 58 works
All ranked researchers at Tydock Pharma (Italy)

What are the most cited papers from Tydock Pharma (Italy)?

The most cited paper from Tydock Pharma (Italy) is "2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1" (João Neres et al., 2014), with 145 citations. Next come "Aggravation of atherosclerosis by hypertension in a subhuman primate model with coarctation of the aorta." (110) and "Long period fiber grating working in reflection mode as valuable biosensing platform for the detection of drug resistant bacteria" (43).

Most cited papers
#PaperReleasedCitations
1 2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 João Neres et al. · ACS Chemical Biology Open access 26 Nov 2014 145
2 Aggravation of atherosclerosis by hypertension in a subhuman primate model with coarctation of the aorta. William Hollander, Irving M. Madoff, John Paddock et al. · Circulation Research Jun 1976 110
3 Long period fiber grating working in reflection mode as valuable biosensing platform for the detection of drug resistant bacteria Giuseppe Quero, Simona Zuppolini, Marco Consales et al. · Sensors and Actuators B Chemical Open access 23 Feb 2016 43
4 Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo-β-lactamases Matteo Santucci, Francesca Spyrakis, Simon Cross et al. · Scientific Reports Open access 12 Dec 2017 41
5 Virtual screening identifies broad-spectrum β-lactamase inhibitors with activity on clinically relevant serine- and metallo-carbapenemases Francesca Spyrakis, Matteo Santucci, Lorenzo Maso et al. · Scientific Reports Open access 29 Jul 2020 36
All 34 most cited papers, with filters and sorting

Which research topics does Tydock Pharma (Italy) publish most on?

By volume in 2022-now: Pharmaceutical Economics and Policy, Health Systems, Economic Evaluations, Quality of Life, Bariatric Surgery and Outcomes and Diet and metabolism studies.

Pharmaceutical Economics…1Pharmaceutical Economics and Policy: 1 fractional worksHealth Systems, Economic…0Health Systems, Economic Evaluations, Quality of Life: 0 fractional worksBariatric Surgery and Ou…0Bariatric Surgery and Outcomes: 0 fractional worksDiet and metabolism studies: 0 fractional worksDigestive system and related health: 0 fractional worksIntellectual Property an…0Intellectual Property and Patents: 0 fractional worksSARS-CoV-2 and COVID-19 Research: 0 fractional worksCOVID-19 Clinical Research Studies: 0 fractional worksLong-Term Effects of COVID-19: 0 fractional worksEconomic and Financial Impacts of Cancer: 0 fractional works
Economics and EconometricsSurgeryPhysiologyGenetics3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Pharmaceutical Economics and Policy Economics and Econometrics 1 works
  2. 2 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 0 works
  3. 3 Bariatric Surgery and Outcomes Surgery 0 works
  4. 4 Diet and metabolism studies Physiology 0 works
  5. 5 Digestive system and related health Genetics 0 works
  6. 6 Intellectual Property and Patents Management of Technology and Innovation 0 works
  7. 7 SARS-CoV-2 and COVID-19 Research Infectious Diseases 0 works
  8. 8 COVID-19 Clinical Research Studies Infectious Diseases 0 works
  9. 9 Long-Term Effects of COVID-19 Neurology 0 works
  10. 10 Economic and Financial Impacts of Cancer Economics and Econometrics 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available59.7%not open40.3%

World: 40% of research is openly available.

with international co-authors34.4%domestic only65.6%

World: 18% is written across borders.

How has Tydock Pharma (Italy)'s research output changed?

Output in 2022-2025 was 5% lower than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Tydock Pharma (Italy) as a percentage of every work published that year, 0.000020% in 2024.

still counting0.00020%0.00040%0.00060%Tydock Pharma (Italy)0.000031% in 202519801990200020102020

Fractional works of Tydock Pharma (Italy) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Modena

All research institutions in Modena

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Tydock Pharma (Italy). Posts are plain text and can be reported.